Trial Profile
Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs GAD65 vaccine (Diamyd) (Primary) ; Ibuprofen; Vitamin D
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms DIABGAD; DIABGAD-1
- 07 May 2018 According to a Diamyd Medical media release, results from this study were published in the Journal of Diabetes Research.
- 07 May 2018 Results presented in a Diamyd Medical media release.
- 19 May 2017 Status changed from active, no longer recruiting to completed.